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Background: We aimed at identifying variables predicting hypoglycemia in elderly type 2 diabetic patients and the
relation to HbA1c values achieved.
Design: Prospective, observational registry in 3810 patients in primary care. Comparison of patients in different age
tertiles: with an age < 60 (young, n=1,253), age 60 to < 70 (middle aged, n=1,184) to those ≥ 70 years (elderly,
n=1,373). Odds Ratios (OR) with 95% confidence intervals (CI) were determined from univariable and multivariable
regression analyses.
Results: Elderly patients had a later diabetes diagnosis, a longer diabetes duration, better glucose control and more
frequent co-morbid disease conditions. Overall 10.7% of patients experienced any severity hypoglycemia within the
last 12 months prior to inclusion. Higher rates of hypoglycemia were observed in the elderly than in the young
after adjusting for differences in HbA1c, fasting and post-prandial blood glucose (OR 1.68; 95%CI 1.16-2.45). This was
particularly true for hypoglycemic episodes without specific symptoms (OR 1.74; 95%CI 1.05-2.89). In a multivariate
model stroke / transitory ischemic attack, the presence of heart failure, clinically relevant depression, sulfonylurea
use and blood glucose self-measurement were associated with hypoglycemic events.
Conclusion: Elderly patients are at an increased risk of hypoglycemia even at comparable glycemic control.
Therefore identified variables associated with hypoglycemia in the elderly such as heart failure, clinically relevant
depression, the use of sulfonylurea help to optimize the balance between glucose control and low levels of
hypoglycemia. Asymptomatic hypoglycemia should not be disregarded as irrelevant but considered as a sign of
possible hypoglycemia associated autonomic failure.Introduction
Providing adequate antidiabetic pharmacotherapy in the
elderly is challenging due to age related co-morbid con-
ditions and geriatric issues such as a loss of sensitivity
towards hypoglycemia [1,2]. Further it appears, that a
proper balance between the benefits of blood glucose
lowering and hypoglycemia is more difficult to achieve
than in younger patients. Low glycosylated hemoglobin
A1c (HbA1c) targets result in an increased risk for
hypoglycemia, and some antidiabetic drugs have been
reported to confer additional risk [3,4].* Correspondence: peter.bramlage@ippmed.de
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reproduction in any medium, provided the orGuidance on how to actually adjust glucose levels in
elderly patients is provided by the European Society of
Cardiology (ESC) [5], the German Society for Diabetes
(DDG) [6] and the American Association of Clinical
Endocrinology (AACE) [7]. These recommend HbA1c
targets of < 6.5% in general while the European Society
for the Study of Diabetes (EASD) [8] and the American
Diabetes Association (ADA) recommend a less strict
HbA1c target of < 7.0% [9]. While these targets also
apply to healthy older adults with a life expectancy of
more than 5 years [10], an HbA1c < 8.0% is deemed
to be sufficient in elderly patients with multiple co-
morbidities, functional disabilities and / or limited life
expectancy. Formal evidence for these recommendations
is however lacking and specific characteristics of elderlyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not been described [11].
The present analysis, based on data of the DiaRegis
(Diabetes Treatment Patterns and Goal Achievement in
primary diabetes care) registry [12-15], aims at determin-
ing patient characteristics and clinical variables in the
elderly that are associated with an increased risk of
hypoglycemia, taking into account specific age related
issues such as co-morbid disease and underlying medical
treatment.Methods
DiaRegis is a prospective, observational, national, multi-
center registry. It is conducted in accordance with the
ethical principles that have their origin in the Declar-
ation of Helsinki and adhere to International Conference
on Harmonization Good Clinical Practice (ICH GCP),
Good Epidemiology Practices (GEP), and applicable regu-
latory requirements. The protocol of this registry was
approved by the ethics committee of the Landesärzte-
kammer Thüringen in Jena, Germany on March 4th
2009. Patients being enrolled into this registry provided
written informed consent.Patients
Patients included: Between June 2009 and March 2010 a
total of 3810 patients with type-2 diabetes aged ≥ 40
years on oral mono or dual oral combination antidiabetic
therapy (no injectables such as insulin and glucagon-like
peptide 1 [GLP-1] analogues) were included in a con-
secutive fashion on a center (physician office) basis. An
additional requirement was that the treating physician
considered an adjustment of antidiabetic pharmacother-
apy to be necessary.
Patients not included: Patients not under regular
supervision of the treating physician, patients with type-1
diabetes, pregnancy, diabetes secondary to malnutrition,
infection or surgery, with maturity onset diabetes of the
young, known cancer or limited life expectancy, acute
emergencies, participation in a clinical trial and patients
with further reasons that make it impossible or highly
problematic for the patient to participate and to come to
the follow-up visits were excluded.
For the present analysis the total cohort of 3,810
patients was divided into age tertiles of almost equal size
aiming to provide sufficient statistical power to the ana-
lyses and to define age groups that are quantitatively
relevant for clinical practice. The tertiles were labeled as
follows: Patients with an age of at least 70 years at base-
line (referred to as the elderly), patients younger than 70
but at least 60 years (middle aged) and an age group
with patients below 60 years (young).Documentation
All variables were obtained by the treating physicians in-
dicating the presence of absence of the disease but not
objectively verified. This may be perceived as a limita-
tion of the present registry but was not possible based
on time and financial constraints. Patient variables were
entered by physicians or their nurses via a secure web-
site directly into an electronic database at the Stiftung
Institut für Herzinfarktforschung, Ludwigshafen, Ger-
many. At this stage they were automatically checked for
plausibility and completeness. Data from the self-
administered paper based patient questionnaire were
transferred to the Clinical Research Organization
Winicker Norimed GmbH, Nürnberg, Germany and
entered into the electronic database.
Definition of hypoglycemia
Hypoglycemia was obtained on an anamnestic, retro-
spective basis (within the last 12 months prior to the
baseline visit). It was classified as mild, moderate or se-
vere. Patients with mild hypoglycemia were defined as
being with or without specific symptoms but manageable
without help. These were usually detected by self-
measurements of blood glucose (<2.22 mmol/l; 40 mg/dl
in any case; 2.22-2.78 mmol/l or 50 mg/dl in case of
symptoms) [12,14]. Patients with moderate hypoglycemia
experienced symptoms of hypoglycemia and required as-
sistance from a second person (e.g. a relative or friend),
but no attention of a medical professional was necessary.
Patients with severe hypoglycemia were seeking medical
attention or were admitted to hospital because of
hypoglycemia.
Statistical analysis
The statistical analyses were performed using SAS ver-
sion 9.2 (Cary, North Carolina, U.S.A.). All descriptive
statistics are based on available cases. Patient character-
istics (Table 1), concomitant disease (Table 1) and anti-
diabetic pharmacotherapy (Table 2) were analyzed with
the Cochran-Armitage or Jonchkheere-Terpstra test.
Adjusted Odds Ratios (ORs) for Figure 1 with 95% con-
fidence intervals (CI) were derived from logistic regres-
sion analyses considering gender, concomitant diseases
(coronary artery disease, peripheral arterial disease,
heart failure and depression) and blood glucose levels
(HbA1c, fasting and postprandial blood glucose). Multi-
variable logistic regression analysis was used to estimate
adjusted ORs for Table 3 with 95%CI for the incidence
of hypoglycemia within the 12 months prior to the
baseline visit. Variables entered into the multivariable
model were identified from univariable analysis and
included age, female gender, HbA1c, fasting blood glu-
cose, coronary artery disease, stroke / transitory ische-
mic attack (TIA), heart failure, depression, sulfonylurea
Table 1 Patient characteristics, laboratory values at baseline and co-morbid disease conditions
Age ≥ 70 years Age < 70 to ≥ 60 years Age < 60 years p-value*
(n=1,373) (n=1,184) (n=1,253)
Median (IQR) or % Median (IQR) or % Median (IQR) or %
Age (years) 74.0 (72.0-78.0) 65.0 (62.0-67.0) 54.0 (49.0-57.0) <0.0001
Women (%) 51.1 45.9 42.5 <0.0001
Diabetes duration (years) 6.8 (3.9-10.6) 6.0 (3.3-9.5) 4.1 (1.9-7.3) <0.0001
Physically active (any sport) 31.0 42.9 47.8 <0.0001
Body Mass Index (kg/m2) 29.0 (26.0-33.0) 31.0 (28.0-35.0) 32.0 (28.0-36.0) <0.0001
Men (kg/m2) 29.0 (26.0-32.0) 30.0 (27.0-33.0) 31.0 (28.0-36.0) <0.0001
Women (kg/m2) 30.0 (27.0-34.0) 32.0 (28.0-36.0) 33.0 (29.0-38.0) <0.0001
Waist circumference (cm) 104 (96.0-113.0) 108 (98–117) 109 (99.0-120.0) <0.0001
HbA1c (%) 7.3 (6.8-7.9) 7.5 (6.9-8.4) 7.6 (6.9-8.9) <0.0001
Fasting plasma glucose (mmol/l) 7.7 (6.4-9.2) 7.8 (6.7-9.4) 8.1 (6.8-10.1) <0.0001
Postprandial plasma glucose (mmol/l) 10.0 (8.6-11.8) 10.2 (8.4-12.2) 10.5 (8.7-13.0) <0.0001
Co-morbidity
Dyslipidemia 64.9 65.5 59.3 <0.01
Hypertension 90.5 86.2 76.0 <0.0001
Coronary heart disease 28.1 16.0 8.5 <0.0001
Myocardial infarction 28.8 37.0 50.0 <0.0001
Stable angina 33.6 26.2 20.0 <0.01
Unstable angina 3.2 3.8 5.1 0.40
PCI 35.2 44.1 52.5 <0.001
Bypass surgery 21.6 21.4 19.8 0.74
Prior stroke / TIA 6.8 4.3 2.5 <0.0001
Heart failure 18.6 7.5 2.6 <0.0001
Peripheral arterial disease 8.2 6.4 3.2 <0.0001
Amputation 1.3 0.6 0.8 0.16
Autonomous neuropathy 4.4 3.5 2.1 <0.01
Peripheral neuropathy 18.4 15.8 8.5 <0.0001
NPDR 5.2 3.5 2.4 <0.001
Proliferative retinopathy 1.0 0.4 0.1 <0.01
Legend: HbA1c, glycosylated hemoglobin A1c; PCI, percutaneous coronary intervention; TIA, transitory ischemic attack; NPDR, non-proliferative retinopathy;
* Cochran-Armitage or Jonchkheere-Terpstra test.
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was produced using a robust method for smoothing by
locally weighted regression (LOESS) with second order
polynomials.
Results
Difference in patient characteristics between elderly and
younger diabetic patients
There were 1,373 elderly patients ≥ 70 years, 1,184
patients between 60 and < 70 years and 1,253 patients
below 60 years (young) (Table 1). Elderly patients were
more frequently female, had a later diabetes diagnosis
and had longer diabetes duration. They were less fre-
quently physically active (any sports) and had a lower
body mass index (BMI) and waist circumference. Glucosecontrol as indicated by HbA1c, fasting and postprandial
glucose levels was significantly better in the elderly.
Elderly patients had a distinct co-morbidity profile:
Hypertension, prior stroke / TIA, peripheral arterial
disease, heart failure, autonomous and peripheral neur-
opathy were substantially more frequent (Table 1). This
also applied to coronary artery disease; it was remark-
able however, that a higher proportion of younger
patients with coronary artery disease (CAD) already
had experienced myocardial infarction (50.0 vs. 28.8%;
p<0.0001), while there were more patients with stable
angina in the elderly (33.6 vs. 20.0%; p<0.01). This was
confirmed by a significantly more frequent use of renin
angiotensin system blocking agents, beta blockers, cal-
cium channel blockers, diuretics, antiplatelet agents and
Table 2 Antidiabetic pharmacotherapy at baseline before therapy adjustment per age group (combinations with a
proportion < 1% were omitted)
Age ≥ 70 years Age < 70 to ≥ 60 years Age < 60 years p-value*
n=1,373, (%) n=1,184, (%) n=1,253, (%)
n % n % n %
Oral monotherapy 973 70.9 777 65.6 867 69.2 0.32
Metformin 700 51.0 616 52.0 751 59.9 <0.0001
Sulfonylureas 205 14.9 101 8.5 81 6.5 <0.0001
Glucosidase inhibitors 27 2.0 22 1.9 15 1.2 0.13
Glinides 29 2.1 23 1.9 9 0.7 <0.01
Thiazolidinediones 5 0.4 11 0.9 6 0.5 0.66
DPP-4 inhibitors 7 0.5 4 0.3 5 0.4 0.65
Oral dual combination 400 29.1 407 34.4 386 30.8 0.32
Met + SU 251 18.3 232 19.6 183 14.6 <0.05
Met + Glukos 12 0.9 12 1.0 6 0.5 0.26
Met + Glin 27 2.0 39 3.3 37 3.0 0.11
Met + Glitaz 47 3.4 62 5.2 75 6.0 <0.01
Met + DPP-4 inhibitors 39 2.8 49 4.1 63 5.0 <0.01
Legend. DPP-4, Dipeptidyl-peptidase 4 inhibitors; OAD, oral antidiabetic drug; * Cochran-Armitage or Jonchkheere-Terpstra test; No GLP-1 analogues or insulins
were prescribed because patients with these antidiabetic drugs at baseline were excluded by the study protocol [12].
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least p<0.01).
Finally there was a noteworthy difference in the use
of antidiabetic drugs at baseline such as lesser use of
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OR (95%CI) OR (95%CI) OR (95%CI)
Female gender (vs. male) 0.98 (0.71-1.34) 0.92 (0.63-1.35) –
Diabetes duration per 10 years 1.30 (1.02-1.65) 1.29 (0.97-1.71) –
Coronary artery disease yes (vs. no) 1.62 (1.16-2.26) 1.11 (0.72-1.71) –
Stroke / TIA yes (vs. no) 2.10 (1.26-3.51) 1.94 (1.04-3.59) 1.96 (1.06-3.62)
Heart Failure yes (vs. no) 1.68 (1.16-2.44) 1.61 (1.02-2.53) 1.63 (1.07-2.49)
Depression yes (vs. no) 3.88 (2.33-6.47) 4.24 (2.35-7.65) 4.20 (2.36-7.46)
Sulfonylurea yes (vs. no) 1.90 (1.38-2.62) 1.71 (1.17-2.49) 1.82 (1.25-2.63)
BG self-measurement yes (vs. no) 2.17 (1.35-3.50) 1.92 (1.18-3.11) 2.00 (1.24-3.23)
Legend: * median values for the cohort of elderly people were taken as the cut-off, corresponds to 7.3% or 138 mg/dl respectively.
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11.0% of all patients reported to have had at least 1 epi-
sode (or more) of hypoglycemia in the 12 months prior
enrolment. This was reported more frequently in elderly
than in younger patients (12.8 vs. 9.0%; p<0.01) (Figure 1).
Further significant differences were seen for symptomatic
episode without a need for help (9.2 vs. 5.6%) and symp-
tomatic episodes with a need for medical assistance (0.7
vs. 0.1%). After adjusting for differences in baseline char-
acteristics such as gender, blood glucose and concomi-
tant disease overall rates remained elevated (OR 1.68;
95%CI 1.16-2.45; p=0.0057 for trend across age groups)
as were hypoglycemic episodes without specific symp-
toms (OR 1.74; 95%CI 1.05-2.89; p=0.0378 for trend
across age groups).
In Figure 2A-C we plotted values for blood glucose
control (HbA1c, fasting and postprandial plasma glu-
cose) against the frequency of anamnestic hypoglycemia
in the three different age groups. The figure illustrates
higher rates of anamnestic hypoglycemia in the elderly
at different HbA1c, fasting and post-prandial blood glu-
cose levels. It appears that for HbA1c values < 7.5% and
fasting blood glucose levels < 6.1-6.7 mg/dl the occur-
rence of hypoglycemia in the elderly is increasing more
dramatically than in younger patients < 60 years.Variables associated with hypoglycemia in the elderly
Noteworthy differences between elderly patients experi-
encing hypoglycemia and those without were a higher
prevalence of CAD, stroke / TIA, heart failure, depres-
sion, sulfonylurea use and blood glucose self measure-
ment. In a stepwise multivariate model, considering
these differences in baseline characteristics stroke / TIA
(OR 1.96; 95%CI 1.06-3.62), the presence of heart failure
(OR 1.63; 95%CI 1.07-2.49), clinically relevant depres-
sion (OR 4.20; 95%CI 2.36-7.46) and sulfonylurea use
(OR 1.82; 95%CI 1.25-2.63) remained predictors of
hypoglycemia in the elderly (Table 3). In addition bloodglucose (BG) self-measurement led to a higher aware-
ness of (subclinical) hypoglycemia (OR 2.00; 95%CI
1.24-3.23).
Discussion
In this analysis elderly patients ≥ 70 years were more
likely to have suffered from any severity (but mostly
asymptomatic) hypoglycemia within the last 12 months
prior to inclusion than younger patients < 60 years at
comparable glycemic control. This is important because
it should result in increased awareness of physicians and
patients towards this severe but sometimes even asymp-
tomatic complication and in an adjustment of treatment
to prevent further complications.
Hypoglycemia in the elderly
It is well known that elderly patients are at an increased
risk for hypoglycemia and often limits their proper man-
agement [16]. Risk factors for hypoglycemia are similar
to those in the young but are highly prevalent in the eld-
erly. These include multiple co-morbidities, polyphar-
macy (≥ 5 medications), chronic renal or hepatic
impairment, poor nutrition, use of sulfonylurea or insu-
lin, acute illness, hypoglycemic unawareness and dimin-
ished counter regulatory responses [17].
Although it has been reported that hypoglycemia is
more frequent in the young [18], rates of symptomatic
hypoglycemia appear to be reduced in the elderly. This
has been attributed to repetitive hypoglycemia leading
to blunted symptomatic and hormonal responses to
subsequent episodes leading to impaired awareness of
hypoglycemia, also called hypoglycemia associated auto-
nomic failure (HAAF) [19]. These patients often experi-
ence glucose concentrations below 2.0 mmol/l without
becoming symptomatic. Furthermore, a number of vari-
ables such as glycemic control, alcohol, exercise, and
age affects and reduces symptomatic and hormonal
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Figure 2 HbA1c (A); Fasting plasma glucose (B); Postprandial
plasma glucose (C) and anamnestic hypoglycemia (within 12
months prior to baseline). Legend: none.
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to hypoglycemia with less autonomic and more promin-
ent neuroglycopenic symptoms [25]. In this group,
hypoglycemia can be misdiagnosed as dementia or
neurological events [26].
Pharmacotherapy and hypoglycemia
Polypharmacy is an important predictor of subsequent
hypoglycemic events [17]. This is exemplified in our study
with a more frequent use of cardiovascular medical treat-
ment (beta blockers and diuretics in particular). Both
drugs not only add to polypharmacy but are considered
to impair glucose control by reducing hypoglycemia
awareness and countermeasures or to simply increase
blood glucose levels directly [27,28]. Antidiabetic treat-
ment was also different in the elderly, who were more fre-
quently treated with sulfonylureas and less frequently
with metformin, thiazolidinediones and DPP-4 inhibitors,
a treatment pattern which was even more pronounced in
elderly who experienced hypoglycemia during the last 12
months. The occurrence of hypoglycemia as a result of
antidiabetic treatment of the elderly casts a cloud over
modern risk adopted medical therapies and foils its
achievement. Not surprisingly the uni- and also multivari-
ate analyses found an elevated risk of hypoglycemia in
those being treated with sulfonylureas. Taken together
polypharmacy and in particular therapies with a remark-
able hypoglycemic potential, such as sulfonylureas, should
be used with caution, especially in patients with co-
morbid disease such as heart failure or CAD, who require
medication that might increase this risk for hypoglycemia.
Variables associated with hypoglycemia in the elderly
Beyond the use of sulfonylureas, stroke / TIA, heart failure
and clinically relevant depression were predicting an
increased risk for hypoglycemia in a multivariate model.
Interestingly also patients who perform blood glucose
self-measurement had an increased risk of (asymptomatic)
hypoglycemia. This may be regarded as a self-fulfilling
prophecy but is important not only because asymptomatic
biochemical hypoglycemia may result in neurological im-
pairment but because severe hypoglycemia may be
masked as being asymptomatic in the elderly [19]. Indeed
we found that the majority of hypoglycemic events in the
elderly were either asymptomatic or symptomatic but
without the need for help.
Although the association of hypoglycemia with depres-
sion has already been described [29,30], it is a finding
with major public health implications. In a study of 99
adult patients with long-standing type-1 diabetes it was
shown that poor sleep quality was independently asso-
ciated with a positive hospital anxiety and depression
scale (HADS), a possible explanation could be the occur-
rence of nocturnal hypoglycemia [29]. Undisputable and
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reductions in health related quality of life as a study in
type-2 diabetes mellitus patients showed and depression
is a major determinant of this. Further research is war-
ranted to evaluate if these mechanisms are solely able to
explain the findings or if other variables should be taken
into account [30].
Blood glucose targets in the elderly
It is important to understand that especially the elderly
gain benefit from an individualized approach, instead of
undifferentiated efforts to lower blood glucose. The ADA
generally considers an HbA1c < 8.0% as being sufficiently
tight in elderly patients with multiple co-morbidities, func-
tional disabilities and / or limited life expectancy [9]. The
DDG proposes a more individualized approach and con-
siders strict HbA1c values to be not very useful [31]. How-
ever, to give an orientation of how elderly patients should
be treated in terms of their blood glucose and HbA1c tar-
gets, the 2010 DDG practice guidelines propose a decision
making process based on the actual health situation of the
patients and his/her functional status. Patients with a good
functional status (no reduction of their autonomy, good
self-management and training skills), and a low level of co-
morbidity (so called ‘go-go’ patients) should aim for an
HbA1c between 6.5-7.0% without hypoglycemia. Patients
with a reduced functional status (reduced autonomy, self-
management and training skills), and multi-morbidity (so
called ‘slow-go’ patients) should aim for an HbA1c of 7.0-
8.0% without hypoglycemia. Only patients with significant
functional reductions or limited life-expectancy (so called
‘no-go’ patients) should not aim for any certain HbA1c
level, rather than to avoid symptoms of diabetes and
hyper- or hypoglycemia. In this group of patients the focus
is to preserve of a maximal quality of life [31-33].
It is important to highlight that the database for suffi-
cient evidence based decisions and an optimal treatment
of the elderly diabetic patients is weak. More efforts are
required to set up a solid database of this steadily in-
creasing group of patients. The necessity to include
more of the elderly into clinical trials on the treatment
of diabetes and to perform functional and cognitive
assessments accordingly is a challenging requirement of
geriatric societies with a high prevalence of diabetes in
order to optimize medical therapy [31].
Results in perspective
Just recently a new consensus statement on the treat-
ment of type-2 diabetes in the elderly was developed by
the International Association of Gerontology and Geria-
trics (IAGG), the European Diabetes Working Party for
Older People (EDWPOP), and the International Task
Force of Experts in Diabetes [34]. They stated that
hypoglycemia is highly prevalent and underrecognized inolder people and that longer-acting sulfonylureas (or in-
sulin) confer an increased risk. In those at high risk sul-
fonylureas should be avoided and DPP-4 inhibitors or, in
the case of a BMI > 35 kg/m2, GLP-1 analogues should
be considered. In addition they recommend not to lower
blood glucose too aggressively in the elderly. These
recommendations are consistent with our own findings
and the potential clinical implications of our work.
Limitations
Despite the considerable strength of the study in docu-
menting real world patients, treatment patterns, co-
morbidity and treatment related events a few limitations
of the present analysis deserve mentioning. 1) The
present analysis only considered oral antidiabetic drugs
for the evaluation of hypoglycemia in the elderly. There-
fore it is consistent with prior data that we identified
sulfonylurea but not insulin as being associated with
events. 2) Hypoglycemic events were recorded on an an-
amnestic basis where physicians and patients were
required to recall events within the last 12 months. The
bias however appears to be reasonably confined because
preliminary data for the first year of follow-up resulted
in similar hypoglycemia rates. 3) While we also consid-
ered to look at the very elderly (80+) we chose a defin-
ition of 70+ as being elderly. This was because of the
quantitative importance of this patient group which
makes up almost one third of patients in clinical prac-
tice. 4) Clinical diagnoses on co-morbid disease condi-
tions were not validated but relied on the physicians’
assessment instead. This is common practice in this type
of registries and cannot be alleviated because of financial
constraints and the acquisition of data in real world clin-
ical practice and its well known constraints of time.
Conclusions
Hypoglycemia is a serious clinical condition which
impacts clinical outcome, even more so in the elderly with
frequent concomitant diseases. Therefore identified vari-
ables associated with hypoglycemia in the elderly such as
heart failure, clinically relevant depression, the use of sul-
fonylurea help to optimize the balance between glucose
control and low levels of hypoglycemia. Asymptomatic
hypoglycemia should not be disregarded as irrelevant but
considered as a sign of possible hypoglycemia associated
autonomic failure.
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